Monday June 26th 2017

Posts Tagged ‘Paolo Zamboni’

Video: Lucie Seguin CCSVI Surgery in Bulgaria

Video: Lucie Seguin CCSVI Surgery in Bulgaria

“It is absolutely disgraceful that Canadians have to travel halfway across the world to get a simple procedure for blocked veins in their necks to be unplugged so they can get relief from their MS symptoms. It is absolutely disgraceful that our politicians and the MS [Read More]

Video: From Serbia With Hope

Video: From Serbia With Hope

CCSVI RTS – Morning program 18.06.2010.- Dr Zivic talks about CCSVI Liberation Treatment in Serbia, Nis. With English Subtitles [Read More]

London mom pins hope on surgery in Bulgaria

London mom pins hope on surgery in Bulgaria

Before she completely loses her ability to walk, Pat O’Connor is taking a shot at a controversial treatment for multiple sclerosis. Despite the fact the procedure isn’t covered by Ontario health insurance, the London single mom has booked an operation at a clinic in [Read More]

 Page 5 of 10  « First  ... « 3  4  5  6  7 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]